Drug Profile
BLNP 006
Alternative Names: BLNP-006Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator BL-&-H
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued Chemically-induced disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in South Korea
- 18 Feb 2019 Clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in South Korea (unspecified route) (BL & H pipeline, February 2019)
- 18 Feb 2019 Discontinued - Clinical-Phase-Unknown for Chemically-induced disorders in South Korea (unspecified route) (BL & H pipeline, February 2019)